

Ofatumumab in AQP4-IgG Seropositive NMOSD

NCT05504694

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Tang-Du Hospital
Enrollment	5 participants

Key Eligibility Criteria

Inclusion (7)

- Diagnosis of NMOSD according to the 2015 International Panel Diagnostic Criteria for NMOSD with AQP4-IgG.
- Clinical evidence of at least 2 relapses (including first attack) in past 24 months with at least 1 relapse occurring in the preceding 12 months.
- Adults aged ≥18 years old.
- Expanded disability status scale (EDSS) score between 0 and 7.5 (inclusive).
- Provision of written informed consent to participate in this study.

... and 2 more (see full listing online)

Exclusion (12)

- Progressive neurological deterioration unrelated to relapses of NMOSD, or presence of neurological findings suspected with PML.
- Pregnant or breastfeeding patients and those with family planning during the study period.
- Patients participating in any other clinical therapeutic study at the screening or within 30 days of screening.
- Patients with splenectomy or history of no spleen, and those with planned surgery (excluding minor surgery) during the study period.
- Presence of uncontrolled severe concurrent diseases; long-term glucocorticoids or immunosuppressants use due to other autoimmune diseases, or presence of other chronic diseases that cannot receiving immunosuppression.

... and 7 more (see full listing online)

Locations (1 total)

Tangdu Hospital, Xi'an, Shaanxi, China